Patrizia Ricci

Patrizia Ricci

Auto-generated profile, based on publicly available information

Patrizia Ricci

Department of Medicine and Surgery University of Perugia Perugia Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci
MBMonia Baldoni
Monia Baldoni
PRPatrizia Ricci
Patrizia Ricci
AZAngela Zampella
Angela Zampella
EDEleonora Distrutti
Eleonora Distrutti
Michele BiagioliMichele Biagioli
Michele Biagioli

2 February 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
Michele BiagioliMichele Biagioli
Michele Biagioli
DCDaniela Capobianco
Daniela Capobianco
ACAdriana Carino
Adriana Carino
SMSilvia Marchianò
Silvia Marchianò
CFChiara Fiorucci
Chiara Fiorucci
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci
A growing body of evidence suggests that probiotic functionality is not accurately predicted by their taxonomy. Here, we have set up a study to investigate the effectiveness of two probiotic formulations containing a blend of seven bacterial species in modulating intestinal inflammation in two rodent models of colitis, induced by treating mice with 2,4,6-Trinitrobenzenesulfonic acid (TNBS) or dextran sodium sulfate (DSS). Despite the taxonomy of the bacterial species in the two probiotic formulations being similar, only one preparation (Blend 2-Vivomixx) effectively attenuated the development of colitis in both models. In the TNBS model of colitis, Blend 2 reduced the expression of pro-inflammatory genes while increasing the production of anti-inflammatory cytokines, promoting the expansion M2 macrophages and the formation of IL-10-producing Treg cells in the colon’s lamina propria. In the DSS model of colitis, disease attenuation and Treg formation was observed only in mice administered with Blend 2, and this effect was associated with intestinal microbiota remodeling and increased formation of lactate, butyrate, and propionate. None of these effects were observed in mice administered with Blend 1 (VSL#3). In summary, we have shown that two probiotic mixtures obtained by combining taxonomically similar species produced with different manufacturing methods exert divergent effects in mouse models of colitis.

21 May 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
ACAdriana Carino
Adriana Carino
SMSilvia Marchianò
Silvia Marchianò
Michele BiagioliMichele Biagioli
Michele Biagioli
CFChiara Fiorucci
Chiara Fiorucci
AZAngela Zampella
Angela Zampella
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci
Non-alcoholic steatohepatitis (NASH) is a progressive, chronic, liver disease whose prevalence is growing worldwide. Despite several agents being under development for treating NASH, there are no drugs currently approved. The Farnesoid-x-receptor (FXR) and the G-protein coupled bile acid receptor 1 (GPBAR1), two bile acid activated receptors, have been investigated for their potential in treating NASH. Here we report that BAR502, a steroidal dual ligand for FXR/GPBAR1, attenuates development of clinical and liver histopathology features of NASH in mice fed a high fat diet (HFD) and fructose (F). By RNAseq analysis of liver transcriptome we found that BAR502 restores FXR signaling in the liver of mice feed HFD–F, and negatively regulates a cluster of genes including Srebf1 (Srepb1c) and its target genes—fatty acid synthase (Fasn) and Cell death-inducing DFF45-like effector (CIDE) genes, Cidea and Cidec—involved in lipid droplets formation and triglycerides storage in hepatocytes. Additionally, BAR502 increased the intestinal expression of Fgf15 and Glp1 and energy expenditure by white adipose tissues. Finally, exposure to BAR502 reshaped the intestinal microbiota by increasing the amount of Bacteroidaceae. In conclusion, we have shown that dual FXR/GPBAR1 agonism might have utility in treatment of NASH.

5 December 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
SMSilvia Marchianò
Silvia Marchianò
Michele BiagioliMichele Biagioli
Michele Biagioli
MBMartina Bordoni
Martina Bordoni
Elva MorrettaElva Morretta
Elva Morretta
CGCristina Di Giorgio
Cristina Di Giorgio
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci
Background: Patients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovascular diseases. FXR and GPBAR1 are 2 bile acid–activated receptors exploited in the treatment of nonalcoholic fatty liver disease: whether dual GPBAR1/FXR agonists synergize with statins in the treatment of the liver and cardiovascular components of nonalcoholic fatty liver disease is unknown. Methods and Results: Investigations of human aortic samples obtained from patients who underwent surgery for aortic aneurysms and Gpbar1 −/− , Fxr −/− , and dual Gpbar1 −/‐ Fxr −/− mice demonstrated that GPBAR1 and FXR are expressed in the aortic wall and regulate endothelial cell/macrophage interactions. The expression of GPBAR1 in the human endothelium correlated with the expression of inflammatory biomarkers. Mice lacking Fxr and Gpbar1 −/− / Fxr −/− display hypotension and aortic inflammation, along with altered intestinal permeability that deteriorates with age, and severe dysbiosis, along with dysregulated bile acid synthesis. Vasomotor activities of aortic rings were altered by Gpbar1 and Fxr gene ablation. In apolipoprotein E −/− and wild‐type mice, BAR502, a dual GPBAR1/FXR agonist, alone or in combination with atorvastatin, reduced cholesterol and low‐density lipoprotein plasma levels, mitigated the development of liver steatosis and aortic plaque formation, and shifted the polarization of circulating leukocytes toward an anti‐inflammatory phenotype. BAR502/atorvastatin reversed intestinal dysbiosis and dysregulated bile acid synthesis, promoting a shift of bile acid pool composition toward FXR antagonists and GPBAR1 agonists. Conclusions: FXR and GPBAR1 maintain intestinal, liver, and cardiovascular homeostasis, and their therapeutic targeting with a dual GPBAR1/FXR ligand and atorvastatin holds potential in the treatment of liver and cardiovascular components of nonalcoholic fatty liver disease.

1 January 2017 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
Fulvio NisiFulvio Nisi
Fulvio Nisi
FMFederico Marturano
Federico Marturano
ENEleonora Natali
Eleonora Natali
AGAntonio Galzerano
Antonio Galzerano
PRPatrizia Ricci
Patrizia Ricci
VPVito Aldo Peduto
Vito Aldo Peduto
BACKGROUND: The management of a septic peritonitis open abdomen is a serious problem for clinicians. Open surgery is associated with several complications such as bleeding and perforation of the bowel. CASE PRESENTATION: The authors report a case of a 59-years-old female who underwent a sigmoid resection with an latero-terminal (L-T) anastomosis for the perforation of a diverticulum. After a few days the patients developed a new widespread peritonitis. At the emergency re-laparotomy, surgeons found dehiscence of the posterior wall of the anastomosis with fecal contamination. At admission in ICU (Intensive Care Unit) the patient had open abdomen with dehiscence of cutaneous and subcutaneous layers. CONCLUSION: Conservative therapy with antibiotic therapy and use of the Vacuum-Assisted Closure ® (VAC) Therapy with a long term continuous saline infusion led to the resolution of the septic shock and to the wound healing. Highlights:

4 April 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
CGCristina Di Giorgio
Cristina Di Giorgio
RRRosalinda Roselli
Rosalinda Roselli
Michele BiagioliMichele Biagioli
Michele Biagioli
MBMartina Bordoni
Martina Bordoni
PRPartizia Ricci
Partizia Ricci
Stefano FiorucciStefano Fiorucci
Stefano Fiorucci
Inflammatory bowel disease (IBD) is a chronic and relapsing disease caused by a dysregulated immune response to host intestinal microbiota that occurs in genetically predisposed individuals. IBD encompasses two major clinical entities: ulcerative colitis (UC), which is limited to the colonic mucosa, and Crohn disease (CD), which might affect any segment of the gastrointestinal tract. Despite the prevalence of IBD is increasing worldwide, therapy remains suboptimal, largely because the variability of causative mechanisms, raising the need to develop individualized therapeutic approaches targeted to each individual patient. In this context, patients-derived intestinal organoids represent an effective tool for advancing our understanding on IBD’ s pathogenesis. Organoid 3D culture systems offer a unique model for dissecting epithelial mechanisms involved IBDs and test individualized therapy, although the lack of a functional immune system and a microbiota, two driving components of the IBD pathogenesis, represent a major barrier for their exploitation in clinical medicine. In this review we have examined how to improve the translational utility of intestinal organoids in IBD and how co-coltures of 3D or 2D organoids and immune cells and/or intestinal microbiota might help to overcome these limitations.